News & Events
News
17 March 2025
Technion Leads Israel in U.S. Patent Approvals
This is one of the key ways the Technion makes a lasting impact on society and the economy
Prestigious Ranking Highlights the University’s Global Innovation Impact.
The Technion – Israel Institute of Technology has once again secured its position as a leader in innovation, ranking first in Israel for the number of U.S. patents granted in 2024. According to the U.S. National Academy of Inventors (NAI), the Technion is also second in Europe and the only Israeli university listed in the global top 100, placing 89th worldwide.
A Testament to Technological Excellence
With 43 patents approved last year, the Technion continues to demonstrate its commitment to scientific and engineering breakthroughs. The university’s strong emphasis on research translation ensures that cutting-edge ideas evolve into practical solutions that drive global industries forward. From medical technologies to advanced materials, the Technion’s patented innovations play a vital role in shaping the future.
“I am extremely proud of our ranking among the world’s top 100 universities and our first-place standing in Israel for the fourth consecutive year,” said Rona Samler, General Manager of T3, the Technion’s commercialization unit. “This recognition is a testament to the excellence of Technion researchers in scientific and engineering innovation and the institution’s strength in translating ideas into research and research into world-changing technologies. This is one of the key ways the Technion makes a lasting impact on society and the economy”.
As the Technion continues to push the boundaries of innovation, its influence on cancer research and technology commercialization remains a powerful force for progress.
Cancer Research at the Forefront of Innovation
The Technion's contributions to cancer research are particularly notable, with numerous patents showcasing its groundbreaking work. These include, among others, Bone Marrow-Targeted Nanoparticle Therapy, developed by Profs. Yuval Shaked and Avi Schroeder; the Metabolic Biomarker Platform for Predicting Immunotherapy Outcomes, developed by Asst. Prof. Keren Yizhak; the Chromatography-on-Chip, developed by Prof. Hossam Haick; and Novel Peptides for Targeting Ubiquitin Chains, developed by Prof. Ashraf Brik.
